Bank of New York Mellon Corp Purchases Shares of 76,330 Alto Neuroscience, Inc. $ANRO

Key Points

• Bank of New York Mellon initiated a position in Alto Neuroscience by purchasing 76,330 shares valued at approximately $2.0 million, representing about 0.22% of the company. Several other institutional investors also increased or initiated holdings.
• Analyst sentiment is generally positive, with eight Buy ratings, two Holds and one Sell. Alto Neuroscience has a consensus rating of “Moderate Buy” and an average price target of $37.25.
• ANRO recently traded at $35.75, near its 52-week high of $37.48, and reported a quarterly loss of $0.65 per share—better than the $0.73 consensus estimate. Analysts expect a full-year loss of $2.68 per share.

Bank of New York Mellon Corp purchased a new position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 76,330 shares of the company's stock, valued at approximately $2,014,000. Bank of New York Mellon Corp owned about 0.22% of Alto Neuroscience as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its holdings in Alto Neuroscience by 14,567.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company's stock worth $3,786,000 after buying an additional 211,222 shares during the period. Perceptive Advisors LLC increased its stake in shares of Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock valued at $45,182,000 after buying an additional 225,500 shares during the period. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the first quarter valued at approximately $8,687,000. Orbimed Advisors LLC raised its holdings in shares of Alto Neuroscience by 34.0% during the first quarter. Orbimed Advisors LLC now owns 167,500 shares of the company's stock valued at $3,765,000 after acquiring an additional 42,500 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Alto Neuroscience in the first quarter worth $538,000.

Analysts Set New Price Targets

ANRO has been the topic of several recent analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. BTIG Research upped their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a "buy" rating in a report on Thursday, August 13th. Wolfe Research started coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They issued an "outperform" rating for the company. Zacks Research raised shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 20th. Finally, Wedbush boosted their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a research report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.25.

Alto Neuroscience Trading Up 0.6%

ANRO opened at $35.75 on Wednesday. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience, Inc. has a 52 week low of $3.50 and a 52 week high of $37.48. The stock has a market cap of $1.40 billion, a PE ratio of -14.77 and a beta of 1.13. The business has a 50 day moving average of $30.21 and a 200-day moving average of $25.08.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. Equities research analysts predict that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.